Frode Edvardsen (f. 1977) er til vanlig fastlege ved Heimdal Medisinske Senter og for tiden lege i spesialisering ved Avdeling for klinisk farmakologi, St. Olavs hospital.
Forfatter har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter.
Burnier M, Santschi V, Favrat B et al. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens Suppl 2003; 21: S37 – 42. [PubMed] [CrossRef]
3.
Ceral J, Habrdova V, Vorisek V et al. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res 2011; 34: 87 – 90. [PubMed] [CrossRef]
4.
Jung O, Gechter JL, Wunder C et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31: 766 – 74. [PubMed] [CrossRef]
5.
Strauch B, Petrák O, Zelinka T et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013; 31: 2455 – 61. [PubMed] [CrossRef]
6.
Tomaszewski M, White C, Patel P et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014; 100: 855 – 61. [PubMed] [CrossRef]
McKillop G, Joy J. Patients’ experience and perceptions of polypharmacy in chronic kidney disease and its impact on adherent behaviour. J Ren Care 2013; 39: 200 – 7. [PubMed] [CrossRef]
10.
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487 – 97. [PubMed] [CrossRef]
11.
Brinker S, Pandey A, Ayers C et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol 2014; 63: 834 – 5. [PubMed] [CrossRef]
12.
Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510 – 26. [PubMed] [CrossRef]
13.
Cuspidi C, Macca G, Sampieri L et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19: 2063 – 70. [PubMed] [CrossRef]
14.
Chung O, Vongpatanasin W, Haverkamp W et al. Potential Cost-Effectiveness Of Therapeutic Drug Monitoring In Patients With Resistant Hypertension. Value Health 2014; 17: A486. [PubMed] [CrossRef]
15.
Kjeldsen SE, Os I. Cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension and improving patients’ adherence. J Hypertens 2014; 32: 2357 – 8. [PubMed] [CrossRef]
16.
Sakshaug S. Legemiddelforbruket i Norge 2010 – 2014. Oslo: Folkehelseinstituttet, 2015.
Får du ikke vist PDF-filen eller vil lagre filen, kan du høyreklikke på PDF-ikonet. Velg «Lagre mål/fil som..» og hent så opp PDF-filen i for eksempel Acrobat Reader.